A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
Price : $35 *
At a glance
- Drugs Abatacept (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 16 Mar 2018 Seventeen subjects were enrolled between April 2014 and October 2015, according to results published in the Blood.
- 16 Mar 2018 Results (n=17) assessing tolerability, efficacy and immune effects of abatacept in patients with steroid-refractory chronic graft-versus-host disease, were published in the Blood.
- 05 Jul 2017 Last checked against the ClinicalTrials.gov record.